Skip to main content
main-content
Top

09-25-2020 | EASD 2020 | Conference coverage | Article

EMPEROR-Reduced: Empagliflozin benefits in HF patients irrespective of diabetes

Lead investigator Milton Packer compares the EMPEROR-Reduced results with those of the DAPA-HF trial, and talks about how SGLT2 inhibitors will impact the treatment of heart failure (6:27).

Read the transcript

Related topics

Virtual EASD Annual Meeting 2020 coverage

Catch-up with news stories and expert commentary.

Image Credits